Cargando…

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)

PURPOSE: Evaluate patients’ and nurses’ experiences, including injection problem frequency, with the somatostatin analogues (SSAs) lanreotide autogel(®) (Somatuline(®) autogel(®), deep subcutaneous) and octreotide long-acting release (LAR) (Sandostatin(®) LAR(®), intramuscular) when treating gastroe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ström, Torbjörn, Kozlovacki, Gordana, Myrenfors, Peter, Almquist, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815752/
https://www.ncbi.nlm.nih.gov/pubmed/31695341
http://dx.doi.org/10.2147/PPA.S213472
_version_ 1783463240870658048
author Ström, Torbjörn
Kozlovacki, Gordana
Myrenfors, Peter
Almquist, Martin
author_facet Ström, Torbjörn
Kozlovacki, Gordana
Myrenfors, Peter
Almquist, Martin
author_sort Ström, Torbjörn
collection PubMed
description PURPOSE: Evaluate patients’ and nurses’ experiences, including injection problem frequency, with the somatostatin analogues (SSAs) lanreotide autogel(®) (Somatuline(®) autogel(®), deep subcutaneous) and octreotide long-acting release (LAR) (Sandostatin(®) LAR(®), intramuscular) when treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS: An observational, cross-sectional study across 2 NET centers in Sweden. Questionnaires based on participants’ most recent injection experience were sent to patients with GEP-NETs treated with octreotide or lanreotide, and to nurses administering these treatments. Nurses were identified via patients completing their questionnaires. Resource use was sourced from Swedish prescription registry records. The planned sample size was 200, based on an estimated proportion of 0.50 and ±7% precision. RESULTS: 119/156 patients (n=53, lanreotide; n=66, octreotide) and 43/53 nurses (n=22, lanreotide; n=21, octreotide) completed questionnaires. Despite smaller recruitment than planned, the endpoint precision was ±9% with 119 participants, and still considered reasonable. More octreotide-treated patients reported problems (18% vs none; P=0.001) and experienced moderate-to-high anxiety pre-injection (11% vs 2%). Patients had similar physical HRQoL scores overall (Short Form-12 mean composite scores: physical: 39.4 vs 37.6; mental: 50.7 vs 49.6). The mean number of lanreotide and octreotide doses dispensed per year were 11.1 and 12.6, respectively (P<0.05). In the lanreotide group, 28% self-injected, while 29% were not aware they could self-inject. In the octreotide group, 3% self-injected and 73% were unaware of the availability of an SSA for self-injection. Most patients (61%) felt well-informed about their disease and treatment. Nurses were generally experienced and felt confident and well-informed about giving SSA injections; however, only 12% felt well-informed about the disease and treatment. CONCLUSION: Those treated with lanreotide reported fewer injection problems and experienced less pre-injection anxiety than those treated with octreotide. SSA choice did not appear to affect patients’ HRQoL. Some patients treated with octreotide were unaware of an SSA with the flexibility of self-injection.
format Online
Article
Text
id pubmed-6815752
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68157522019-11-06 Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET) Ström, Torbjörn Kozlovacki, Gordana Myrenfors, Peter Almquist, Martin Patient Prefer Adherence Original Research PURPOSE: Evaluate patients’ and nurses’ experiences, including injection problem frequency, with the somatostatin analogues (SSAs) lanreotide autogel(®) (Somatuline(®) autogel(®), deep subcutaneous) and octreotide long-acting release (LAR) (Sandostatin(®) LAR(®), intramuscular) when treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS: An observational, cross-sectional study across 2 NET centers in Sweden. Questionnaires based on participants’ most recent injection experience were sent to patients with GEP-NETs treated with octreotide or lanreotide, and to nurses administering these treatments. Nurses were identified via patients completing their questionnaires. Resource use was sourced from Swedish prescription registry records. The planned sample size was 200, based on an estimated proportion of 0.50 and ±7% precision. RESULTS: 119/156 patients (n=53, lanreotide; n=66, octreotide) and 43/53 nurses (n=22, lanreotide; n=21, octreotide) completed questionnaires. Despite smaller recruitment than planned, the endpoint precision was ±9% with 119 participants, and still considered reasonable. More octreotide-treated patients reported problems (18% vs none; P=0.001) and experienced moderate-to-high anxiety pre-injection (11% vs 2%). Patients had similar physical HRQoL scores overall (Short Form-12 mean composite scores: physical: 39.4 vs 37.6; mental: 50.7 vs 49.6). The mean number of lanreotide and octreotide doses dispensed per year were 11.1 and 12.6, respectively (P<0.05). In the lanreotide group, 28% self-injected, while 29% were not aware they could self-inject. In the octreotide group, 3% self-injected and 73% were unaware of the availability of an SSA for self-injection. Most patients (61%) felt well-informed about their disease and treatment. Nurses were generally experienced and felt confident and well-informed about giving SSA injections; however, only 12% felt well-informed about the disease and treatment. CONCLUSION: Those treated with lanreotide reported fewer injection problems and experienced less pre-injection anxiety than those treated with octreotide. SSA choice did not appear to affect patients’ HRQoL. Some patients treated with octreotide were unaware of an SSA with the flexibility of self-injection. Dove 2019-10-23 /pmc/articles/PMC6815752/ /pubmed/31695341 http://dx.doi.org/10.2147/PPA.S213472 Text en © 2019 Ström et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ström, Torbjörn
Kozlovacki, Gordana
Myrenfors, Peter
Almquist, Martin
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
title Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
title_full Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
title_fullStr Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
title_full_unstemmed Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
title_short Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
title_sort patient and nurse experience of using somatostatin analogues to treat gastroenteropancreatic neuroendocrine tumors: results of the somatostatin treatment experience trial (street)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815752/
https://www.ncbi.nlm.nih.gov/pubmed/31695341
http://dx.doi.org/10.2147/PPA.S213472
work_keys_str_mv AT stromtorbjorn patientandnurseexperienceofusingsomatostatinanaloguestotreatgastroenteropancreaticneuroendocrinetumorsresultsofthesomatostatintreatmentexperiencetrialstreet
AT kozlovackigordana patientandnurseexperienceofusingsomatostatinanaloguestotreatgastroenteropancreaticneuroendocrinetumorsresultsofthesomatostatintreatmentexperiencetrialstreet
AT myrenforspeter patientandnurseexperienceofusingsomatostatinanaloguestotreatgastroenteropancreaticneuroendocrinetumorsresultsofthesomatostatintreatmentexperiencetrialstreet
AT almquistmartin patientandnurseexperienceofusingsomatostatinanaloguestotreatgastroenteropancreaticneuroendocrinetumorsresultsofthesomatostatintreatmentexperiencetrialstreet